Zymeworks Inc. (ZYME)

25.96 0.16 (0.62%)

As of 2026-04-02 18:27:48 EST

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.

Traded asNasdaq: ZYME
ISINUS98985Y1082
CIK0001937653
LEI894500AHOYAGYLYZJL67
EIN883099146
Sector—
IndustryPharmaceutical Preparations
CEOKenneth Galbraith
Employees275
Fiscal Year End1231
Address108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709
Phone302-274-8744
Websitehttp://www.zymeworks.com/
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
ZYMEZymeworks Inc.2026-04-02 18:27:4825.960.160.62
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
ZYME0001937653Zymeworks Inc.US98985Y1082894500AHOYAGYLYZJL67883099146Nasdaq2834Pharmaceutical Preparations1231DE108 PATRIOT DRIVE, SUITE AMIDDLETOWNDE19709UNITED STATESUS302-274-8744108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709Zymeworks Delaware Inc.—2003Kenneth Galbraith275http://www.zymeworks.com/649,500,00074,638,41373,749,607Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.2026-04-02 17:00:22
This is a preview of the latest data. Subscribe to access the full data.
ZYME Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
ZYME Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
2025649,500,000161,400,00033.06773,749,6074,172,7245.9973
2024488,100,00019,600,0004.183669,576,883-991,339-1.4048
2023468,500,000162,500,00053.104670,568,2226,431,29410.0274
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Leone PattersonChief Business Officer, CFO, VP2024161,66750,000099,8496,0632,907,982
Kenneth GalbraithChair, President, CEO2024654,83302,112,000361,652139,4595,253,616
Kenneth GalbraithChair, President, CEO2023625,45201,144,000321,65189,1463,374,876
Neil KlompasPresident, COO2023321,568—468,00001,007,8012,125,732
Christopher AstleCFO, SVP2023410,093—252,000124,895147,2301,191,820
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
2025264
2024286
2023277
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue105,965,00076,304,00076,012,000
Cost Of Revenue———
Gross Profit———
Research And Development Expenses137,000,000134,621,000143,619,000
General And Administrative Expenses61,514,00061,506,00070,446,000
Operating Expenses198,514,000213,414,000214,065,000
Operating Income-92,549,000-137,110,000-138,053,000
Net Income-81,130,000-122,695,000-118,674,000
Earnings Per Share Basic-1.08-1.62-1.72
Earnings Per Share Diluted-1.08-1.62-1.72
Weighted Average Shares Outstanding Basic75,404,89775,846,68168,863,010
Weighted Average Shares Outstanding Diluted75,413,39675,878,73868,863,010
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents41,157,00066,103,000157,557,000
Marketable Securities Current——216,770,000
Accounts Receivable4,638,00055,815,00019,477,000
Inventories———
Non Trade Receivables———
Other Assets Current———
Total Assets Current248,767,000300,451,000412,926,000
Marketable Securities Non Current——82,148,000
Property Plant And Equipment15,502,00017,650,00019,847,000
Other Assets Non Current—017,628,000
Total Assets Non Current97,760,000162,640,000167,954,000
Total Assets346,527,000463,091,000580,880,000
Accounts Payable4,403,0003,903,0006,212,000
Deferred Revenue2,418,00025,588,0003,699,000
Short Term Debt———
Other Liabilities Current83,000128,0001,811,000
Total Liabilities Current42,318,00088,294,00055,763,000
Long Term Debt———
Other Liabilities Non Current278,000923,0001,701,000
Total Liabilities Non Current35,708,00036,029,00060,311,000
Total Liabilities78,026,000124,323,000116,074,000
Common Stock1,105,176,0001,015,618,000997,227,000
Retained Earnings-953,160,000-830,335,000-677,437,000
Accumulated Other Comprehensive Income-6,079,000-6,952,000-6,603,000
Total Shareholders Equity268,501,000338,768,000464,806,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization3,669,0004,188,0007,462,000
Share Based Compensation Expense28,034,00017,792,0008,102,000
Other Non Cash Income Expense———
Change In Accounts Receivable-51,200,00036,359,000-13,922,000
Change In Inventories———
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable-23,648,00014,335,000-44,768,000
Change In Other Liabilities———
Cash From Operating Activities-33,005,000-110,044,000-118,303,000
Purchases Of Marketable Securities196,061,000283,743,000553,249,000
Sales Of Marketable Securities225,076,000325,565,000350,073,000
Acquisition Of Property Plant And Equipment1,521,0001,991,0002,474,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities26,663,00038,756,000-207,253,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock0026,233,000
Repurchase Of Common Stock41,695,00030,051,000—
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities16,904,0008,857,0005,006,000
Cash From Financing Activities-18,559,000-20,452,00081,847,000
Change In Cash-24,946,000-91,454,000-243,355,000
Cash At End Of Period41,157,00066,103,000157,557,000
Income Taxes Paid1,350,0003,179,000—
Interest Paid———
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share-1.08-1.62-1.72
Price To Earnings Ratio-24.3796-9.037-6.0407
Earnings Growth Rate-33.3333-5.814-190.0524
Price Earnings To Growth Ratio0.73141.55440.0318
Book Value Per Share3.56084.46656.7497
Price To Book Ratio7.39443.27771.5393
Ebitda-76,111,000-115,328,000-111,212,000
Enterprise Value———
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio———
Capital Expenditures1,521,0001,991,0002,596,000
Free Cash Flow-34,526,000-112,035,000-120,899,000
Return On Equity-0.3022-0.3622-0.2553
One Year Beta0.78730.92610.8712
Three Year Beta0.83511.00720.9954
Five Year Beta0.93510.93780.9169
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Galbraith KennethDirector, Chair & CEO2026-01-1264,000A257,266
Galbraith KennethDirector, Chair & CEO2026-01-1230,424D226,842
Galbraith KennethDirector, Chair & CEO2026-01-1264,000D128,000
Galbraith KennethDirector, Chair & CEO2026-01-12216,000A216,000
Galbraith KennethDirector, Chair & CEO2026-01-12144,000A144,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Global Wealth Strategies & Associates2026-03-3140,9401,63525.0398
Seven Fleet Capital Management LP2025-12-31542,39820,60026.33
GOLDMAN SACHS GROUP INC2025-12-3111,064,051420,20726.33
HSBC HOLDINGS PLC2025-12-31476,18217,86826.65
Caitong International Asset Management Co., Ltd2025-12-3136,8361,39926.3302
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
Global X Funds2026-01-31Global X Russell 2000 ETFRSSL22,480506,474.40.0366
INVESCO EXCHANGE-TRADED FUND TRUST2026-01-31Invesco RAFI US 1500 Small-Mid ETFPRFZ82,7681,864,763.040.0697
VALUED ADVISERS TRUST2026-01-31Institutional Class SharesDSCIX15,069339,504.571.1003
VANGUARD EXPLORER FUND2026-01-31Admiral SharesVEXRX48,2001,085,9460.0052
VANGUARD EXPLORER FUND2026-01-31Investor SharesVEXPX48,2001,085,9460.0052
This is a preview of the latest data. Subscribe to access the full data.